09/01/2021
Mydecine COO Damon Michaels is back on The Dales Report!
In this episode, Michaels shares our exciting five-year partnership with Johns Hopkins University, reflects on how fast the industry has progressed in the last 12 months, our advancements with our lead drug candidates MYCO-001 AND MYCO-004, and our goals to expand the treatment options for those that need it.
In our first interview with Mydecine Innovations Group (NEO: MYCO)(OTCMKTS: MYCOF) we talked about the five-year agreement with the Johns Hopkins University ...